Nonmyeloablative allogeneic immunotherapy for solid tumors.
Over the past decade, considerable advances have been made in the field of allogeneic hematopoietic stem cell transplantation. Recognition that transplanted donor immune cells can cure patients with leukemia has led to the development of nonmyeloablative or "low-intensity" conditioning regimens, which have expanded the application of allogeneic transplantation to a growing number of hematological malignancies. The improved safety and preliminary success of this transplant approach have justified applying allogeneic immunotherapy to patients with treatment-refractory solid tumors.
Childs
Richard W
RW
Allogeneic Hematopoietic Cell Transplant Unit, Hematology Branch, National Heart, Lung, and Blood Institutes, National Institutes of Health, Bethesda, Maryland 20892, USA. childsr@nih.gov
Barrett
John
J
D000818:Animals; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology / Q000601:surgery*; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous